Statement of Changes in Beneficial Ownership (Form 4)

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person * Qiming Corporate GP VI, Ltd. 2. Issuer Name and Ticker or Trading Symbol Alamar Biosciences, Inc. [ALMR] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director __X__ 10% Owner _____ Officer (give title below) _____ Other (specify below) (Last) (First) (Middle) C/O MAPLES CORPORATE SERVICES LIMITED, PO BOX 309 3. Date of Earliest Transaction (Month/Day/Year) 10/19/2026 (Street) UGLAND HOUSE KY1-1104 4. If Amendment, Date Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) ___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 10/19/2026 S 1,320 D $26.34(1) 180,808 I See footnote(2) Common Stock 10/19/2026 S 49,044 D $26.34(1) 6,719,561 I See footnote(3) Common Stock 10/19/2026 S 11,443 D $26.34(1) 1,567,881 I See footnote(4) Common Stock 10/19/2026 S 13,701 D $26.34(1) 1,877,116 I See footnote(5) Common Stock 10/20/2026 S 200 D $26.63(6) 180,608 I See footnote(2) Common Stock 10/20/2026 S 1,947 D $27.93(7) 178,661 I See footnote(2) Common Stock 10/20/2026 S 335 D $28.44(8) 178,326 I See footnote(2) Common Stock 10/20/2026 S 7,415 D $26.63(6) 6,712,146 I See footnote(3) Common Stock 10/20/2026 S 72,373 D $27.93(7) 6,639,773 I See footnote(3) Common Stock 10/20/2026 S 12,447 D $28.44(8) 6,627,326 I See footnote(3) Common Stock 10/20/2026 S 1,730 D $26.63(6) 1,566,151 I See footnote(4) Common Stock 10/20/2026 S 16,887 D $27.93(7) 1,549,264 I See footnote(4) Common Stock 10/20/2026 S 2,904 D $28.44(8) 1,546,360 I See footnote(4) Common Stock 10/20/2026 S 2,072 D $26.63(6) 1,875,044 I See footnote(5) Common Stock 10/20/2026 S 20,217 D $27.93(7) 1,854,827 I See footnote(5) Common Stock 10/20/2026 S 3,477 D $28.44(8) 1,851,350 I See footnote(5)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
	Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.		SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)

2. Conversion or Exercise Price of Derivative Security

3. Transaction Date (Month/Day/Year)

3A. Deemed Execution Date, if any (Month/Day/Year)

4. Transaction Code (Instr. 8)

5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)

6. Date Exercisable and Expiration Date (Month/Day/Year)

7. Title and Amount of Underlying Securities (Instr. 3 and 4)

8. Price of Derivative Security (Instr. 5)

9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)

10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)

11. Nature of Indirect Beneficial Ownership (Instr. 4)

Code

V

(A)

(D)

Date Exercisable

Expiration Date

Title

Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
Qiming Corporate GP VI, Ltd. C/O MAPLES CORPORATE SERVICES LIMITED PO BOX 309 UGLAND HOUSE KY1-1104		X
Qiming Managing Directors Fund VI, L.P. C/O MAPLES CORPORATE SERVICES LIMITED PO BOX 309 UGLAND HOUSE KY1-1104		X
Qiming Venture Partners VI, L.P. C/O MAPLES CORPORATE SERVICES LIMITED PO BOX 309 UGLAND HOUSE KY1-1104		X
Qiming GP VIII, LLC C/O MAPLES CORPORATE SERVICES LIMITED PO BOX 309 UGLAND HOUSE KY1-1104		X
Qiming Venture Partners VIII Investments, LLC C/O MAPLES CORPORATE SERVICES LIMITED PO BOX 309 UGLAND HOUSE KY1-1104		X
Qiming GP VIII-HC, LLC C/O MAPLES CORPORATE SERVICES LIMITED PO BOX 309 UGLAND HOUSE KY1-1104		X
Qiming Venture Partners VIII-HC, L.P. C/O MAPLES CORPORATE SERVICES LIMITED PO BOX 309 UGLAND HOUSE KY1-1104		X

Signatures

Qiming Corporate GP VI, Ltd By: /s/ Ho Man LAM/Authorized Signatory		10/21/2026
**Signature of Reporting Person		Date
Qiming Managing Directors Fund VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory		10/21/2026
**Signature of Reporting Person		Date
Qiming Venture Partners VI, L.P. By: /s/ Ho Man LAM/Authorized Signatory		10/21/2026
**Signature of Reporting Person		Date
Qiming GP VIII, LLC By: /s/ Ho Man LAM/Authorized Signatory		10/21/2026
**Signature of Reporting Person		Date
Qiming Venture Partners VIII Investments, LLC By: /s/ Ho Man LAM/Manager		10/21/2026
**Signature of Reporting Person		Date
Qiming GP VIII-HC, LLC By: /s/ Ho Man LAM/Authorized Signatory		10/21/2026
**Signature of Reporting Person		Date
Qiming Venture Partners VIII-HC, L.P. By: /s/ Ho Man LAM/Authorized Signatory		10/21/2026
**Signature of Reporting Person		Date

Explanation of Responses:

*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.2 to $26.52, inclusive. The reporting person undertakes to provide to Alamar Biosciences, Inc., any security holder of Alamar Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the footnotes (1) through (4) to this Form 4.
(2)	These shares are held of record by Qiming Managing Directors Fund VI, L.P. ("Qiming Managing Directors"). Qiming Corporate GP VI, Ltd. ("Qiming Corporate") serves as the general partner of Qiming Managing Directors and may be deemed to have voting and dispositive power over the shares held by Qiming Managing Directors. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
(3)	These shares are held of record by Qiming Venture Partners VI, L.P., ("Qiming Venture Partners VI"). Qiming Corporate, through one intermediary, serves as the indirect general partner of Qiming Venture Partners VI and may be deemed to have voting and dispositive power over the shares held by Qiming Venture Partners VI. Qiming Corporate disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
(4)	These shares are held of record by Qiming Venture Partners VIII Investments, LLC ("QVP VIII LLC"). Qiming GP VIII, LLC, through two parallel intermediaries, serves as the indirect general partner of QVP VIII LLC and may be deemed to have voting and dispositive power over the shares held by QVP VIII LLC. Qiming GP VIII, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
(5)	These shares are held of record by Qiming Venture Partners VIII-HC, L.P. ("QVP VIII-HC"). Qiming GP VIII-HC, LLC serves as the general partner of QVP VIII-HC and may be deemed to have voting and dispositive power over the shares held by QVP VIII-HC. Qiming GP VIII-HC, LLC disclaims beneficial ownership of such shares, except to the extent of its proportionate pecuniary interest therein.
(6)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.20 to $26.96, inclusive.
(7)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.28 to $28.27, inclusive.
(8)	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.28 to $28.73, inclusive.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.